2022
DOI: 10.1111/1759-7714.14583
|View full text |Cite
|
Sign up to set email alerts
|

Perivascular epithelioid cell tumor of the lung: A case report and literature review

Abstract: The perivascular epithelioid cell tumor (PEComa) is a rare tumor of interstitial origin characterized by several immunological and muscle cell markers. The clear cell sugar tumor (CCST) of the lung is a type of PEComa defined by thin cell walls and high levels of glycogen in the cytoplasm. We herein reported the case of a 48-year-old male with a recurrence of lung CCST. The preoperative diagnosis of the lung mass was performed by percutaneous needle biopsy. During the thoracoscopic resection, multiple adhesion… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 30 publications
0
0
0
Order By: Relevance
“…
Perivascular epithelioid cell tumors pose a significant clinical challenge, necessitating innovative and targeted therapeutic strategies for effective treatment. 1 The conventional paradigm of drug development has been augmented by drug repositioning, particularly leveraging the wealth of knowledge surrounding FDA-approved compounds. Within this context, our research embarks on a comprehensive exploration of the therapeutic potential inherent in FDA-approved Sirolimus analogs for the treatment of PEComas.
…”
mentioning
confidence: 99%
“…
Perivascular epithelioid cell tumors pose a significant clinical challenge, necessitating innovative and targeted therapeutic strategies for effective treatment. 1 The conventional paradigm of drug development has been augmented by drug repositioning, particularly leveraging the wealth of knowledge surrounding FDA-approved compounds. Within this context, our research embarks on a comprehensive exploration of the therapeutic potential inherent in FDA-approved Sirolimus analogs for the treatment of PEComas.
…”
mentioning
confidence: 99%